%0 Journal Article
%T 达沙替尼治疗儿童慢性粒细胞白血病的进展分析<br>Analysis of the Progress of Dasatinib in the Treatment of Chronic Myeloid Leukemia in Children
%A 覃欢
%A 于洁
%J Advances in Clinical Medicine
%P 6189-6194
%@ 2161-8720
%D 2021
%I Hans Publishing
%R 10.12677/ACM.2021.1112918
%X 慢性粒细胞白血病(Chronic Myeloid Leukemia, CML)是一种恶性肿瘤性疾病。该病在儿童中罕见，治疗多参考成人经验。目前有几种酪氨酸激酶抑制剂已被批准用于治疗儿童CML。达沙替尼治疗儿童慢性粒细胞性白血病是有效的，但其报道少，本文总结其在儿童CML中的疗效及安全性等。<br />
Chronic Myeloid Leukemia is a malignant tumor disease. It is rare in children, requiring extrapolation from the treatment of adults. Several tyrosine kinase inhibitors (TKIs) are approved for the treatment of children’s CML. Pediatric CML is effectively treated with long-term targeted therapy using dasatinib, but there are few reports, in this review, we summarize its efficacy and safety in children’s CML.
%K 慢性粒细胞白血病，儿童，达沙替尼<br>Chronic Myeloid Leukemia
%K Children
%K Dasatinib
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=47677